Form 8-K - Current report:
SEC Accession No. 0001029142-25-000047
Filing Date
2025-02-20
Accepted
2025-02-20 16:03:54
Documents
15
Period of Report
2025-02-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dvax-20250220.htm   iXBRL 8-K 29087
2 EX-99.1 dvax-exx991xearningspressr.htm EX-99.1 139510
6 a1.jpg GRAPHIC 1710
  Complete submission text file 0001029142-25-000047.txt   314388

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dvax-20250220.xsd EX-101.SCH 1854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dvax-20250220_lab.xml EX-101.LAB 22804
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dvax-20250220_pre.xml EX-101.PRE 13115
17 EXTRACTED XBRL INSTANCE DOCUMENT dvax-20250220_htm.xml XML 3014
Mailing Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 25645197
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)